We are live on ! Find out more
ARMO

ARMO BioSciences, Inc. Common Stock
ARMO

Delisted

ARMO was delisted on the 21st of June, 2018.

Back to rankings

0 hedge funds and large institutions have $0 invested in ARMO BioSciences, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 63 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 65 → 0 (-65)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $509M → $0 (-$509M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 63

Holders
–
Holders Change
-65
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
63
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$154M
2
AI
Alphabet Inc
California
-$45.4M
3
ACA
Avoro Capital Advisors
New York
-$45.2M
4
BlackRock
BlackRock
New York
-$30.8M
5
HH
HSG Holding
Hong Kong
-$30.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
VIA
26
Vident Investment Advisory
Georgia
– -$2.17M -74,279 Closed
CS
27
Candriam SCA
Luxembourg
– -$2.77M -74,000 Closed
Northern Trust
28
Northern Trust
Illinois
– -$2.74M -73,138 Closed
Geode Capital Management
29
Geode Capital Management
Massachusetts
– -$2.63M -70,311 Closed
Goldman Sachs
30
Goldman Sachs
New York
– -$2.51M -67,026 Closed
AllianceBernstein
31
AllianceBernstein
Tennessee
– -$1.87M -50,000 Closed
MWNA
32
Marshall Wace North America
New York
– -$1.76M -46,933 Closed
PCA
33
Private Capital Advisors
Connecticut
– -$1.74M -46,574 Closed
Alyeska Investment Group
34
Alyeska Investment Group
Illinois
– -$1.7M -45,403 Closed
LCM
35
Landscape Capital Management
New Jersey
– -$1.38M -36,935 Closed
Charles Schwab
36
Charles Schwab
California
– -$1.23M -32,953 Closed
Bank of New York Mellon
37
Bank of New York Mellon
New York
– -$761K -20,322 Closed
Morgan Stanley
38
Morgan Stanley
New York
– -$759K -20,287 Closed
PIM
39
Platinum Investment Management
Australia
– -$748K -20,000 Closed
LCM
40
Laurion Capital Management
New York
– -$669K -17,874 Closed
TD Asset Management
41
TD Asset Management
Ontario, Canada
– -$514K -13,740 Closed
DS
42
DRW Securities
Illinois
– -$479K -12,810 Closed
TA
43
Teachers Advisors
New York
– -$462K -12,362 Closed
CIP
44
Chartwell Investment Partners
Pennsylvania
– -$459K -12,280 Closed
MIM
45
MetLife Investment Management
New Jersey
– -$408K -10,912 Closed
TCIM
46
TIAA CREF Investment Management
New York
– -$407K -10,874 Closed
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
– -$390K -10,427 Closed
Deutsche Bank
48
Deutsche Bank
Germany
– -$331K -8,889 Closed
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
– -$251K -6,700 Closed
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
– -$227K -6,076 Closed
1
2
3

ARMO Hedge Fund Activity: Q2 2018 in Review

0 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in ARMO BioSciences, Inc. Common Stock (ARMO) for Q2 2018, worth a combined $0 — down 100% from $509M a quarter earlier.

Sellers outnumbered buyers: 63 funds closed out of ARMO and 0 opened new positions — a net loss of 63 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was OrbiMed, exiting entirely with an estimated $154M sold.

  • 0 institutional investors held ARMO BioSciences, Inc. Common Stock (ARMO) as of Q2 2018, down from 65 in Q1 2018.
  • Funds reported $0 of ARMO BioSciences, Inc. Common Stock stock for Q2 2018, down 100% quarter-over-quarter.
  • 0 funds opened new ARMO BioSciences, Inc. Common Stock positions in Q2 2018 and 63 closed out, a net change of -63 holders.
  • The largest ARMO BioSciences, Inc. Common Stock seller in Q2 2018 was OrbiMed, an estimated $154M sold.

Based on aggregated 13F filings for Q2 2018.